FcRn inhibitors for myasthenia gravis

White, Laura M and Clay, Fiona J and Forbes, Anne-Marie and Keh, Ryan Yann Shern and Lilleker, James B and Spillane, Jennifer and Storms, Karen and Dodd, Katherine C and Sussman, Jon (2025) FcRn inhibitors for myasthenia gravis. Cochrane Database Syst. Rev., 8 (8): CD016097. ISSN 1465-1858

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.